300199 翰宇药业
交易中 12-23 11:04:39
资讯
新帖
简况
翰宇药业（300199）12月20日主力资金净买入7085.85万元
证券之星 · 09:10
翰宇药业（300199）12月20日主力资金净买入7085.85万元
A股医药板块逆势拉升，鲁抗医药午后涨停，翰宇药业、热景生物涨超10%，成都先导、广誉远、昆药集团、联环药业等跟涨。
美港电讯 · 12-20 14:06
A股医药板块逆势拉升，鲁抗医药午后涨停，翰宇药业、热景生物涨超10%，成都先导、广誉远、昆药集团、联环药业等跟涨。
翰宇药业旗下公司与龙麻科技签订战略合作协议
美港电讯 · 12-11
翰宇药业旗下公司与龙麻科技签订战略合作协议
12月10日翰宇药业现1笔大宗交易 机构净买入202.95万元
证券之星 · 12-10
12月10日翰宇药业现1笔大宗交易 机构净买入202.95万元
翰宇药业(300199.SZ)：DS3拟向公司采购约1400万美元GLP-1原料药
智通财经 · 12-05
翰宇药业(300199.SZ)：DS3拟向公司采购约1400万美元GLP-1原料药
翰宇药业最新公告：与DS3签订1.02亿元GLP-1原料药供应协议
证券之星 · 12-05
翰宇药业最新公告：与DS3签订1.02亿元GLP-1原料药供应协议
翰宇药业最新公告：再次收到Hikma的利拉鲁肽注射液采购需求订单
证券之星 · 12-04
翰宇药业最新公告：再次收到Hikma的利拉鲁肽注射液采购需求订单
翰宇药业前总裁被判3年半，与“胡润富豪”共事16年！
市场资讯 · 11-17
翰宇药业前总裁被判3年半，与“胡润富豪”共事16年！
概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线
格隆汇 · 11-17
概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线
翰宇药业：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月
美港电讯 · 11-13
翰宇药业：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月
翰宇药业最新公告：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月
证券之星 · 11-13
翰宇药业最新公告：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月
翰宇药业（300199）2024年三季报简析：亏损收窄，短期债务压力上升
证券之星 · 10-31
翰宇药业（300199）2024年三季报简析：亏损收窄，短期债务压力上升
翰宇药业最新公告：第三季度净利润亏损2444.68万元
证券之星 · 10-29
翰宇药业最新公告：第三季度净利润亏损2444.68万元
翰宇药业最新公告：“醋酸阿托西班注射液”获得泰国上市许可
证券之星 · 10-29
翰宇药业最新公告：“醋酸阿托西班注射液”获得泰国上市许可
翰宇药业最新公告：Hikma拟向公司采购约8400万元利拉鲁肽注射液
证券之星 · 10-17
翰宇药业最新公告：Hikma拟向公司采购约8400万元利拉鲁肽注射液
A股减肥药板块局部异动，常山药业直线拉升逼近20CM涨停，博瑞医药、翰宇药业、金凯生科、百花医药等跟涨。
美港电讯 · 10-17
A股减肥药板块局部异动，常山药业直线拉升逼近20CM涨停，博瑞医药、翰宇药业、金凯生科、百花医药等跟涨。
翰宇药业(300199.SZ)：利拉鲁肽注射液上市申请获受理
智通财经 · 10-14
翰宇药业(300199.SZ)：利拉鲁肽注射液上市申请获受理
翰宇药业最新公告：司美格鲁肽原料药获得DMF备案号
证券之星 · 09-25
翰宇药业最新公告：司美格鲁肽原料药获得DMF备案号
翰宇药业：司美格鲁肽原料药获得DMF备案号
美港电讯 · 09-25
翰宇药业：司美格鲁肽原料药获得DMF备案号
翰宇药业(300199.SZ)：司美格鲁肽原料药获美国DMF备案号
智通财经 · 09-25
翰宇药业(300199.SZ)：司美格鲁肽原料药获美国DMF备案号
暂无数据
公司概况
公司名称：
深圳翰宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-07
主营业务：
深圳翰宇药业股份有限公司是一家专业从事多肽药物研发、生产和销售的国家级高新技术企业，主要产品包括多肽制剂药品、多肽原料药、客户定制肽、美容肽、固体制剂药品、医疗器械、多肽护肤品、大健康类产品等多个系列。公司上榜2023年广东制造业企业500强，并获得深圳市“专精特新”企业认定；翰宇武汉公司荣膺黄陂区“优秀先进制造业企业”，再次凸显公司高水准的质量优势。
发行价格：
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":14.98,"timestamp":1734923079000,"preClose":15.72,"halted":0,"volume":46345405,"delay":0,"floatShares":706000000,"shares":883000000,"eps":-0.4168,"marketStatus":"交易中","marketStatusCode":2,"change":-0.74,"latestTime":"12-23 11:04:39","open":15.46,"high":15.89,"low":14.7,"amount":700000000,"amplitude":0.0757,"askPrice":14.98,"askSize":275,"bidPrice":14.97,"bidSize":46,"shortable":0,"etf":0,"ttmEps":-0.4168,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1734924600000},"adr":0,"adjPreClose":15.72,"symbolType":"stock","openAndCloseTimeList":[[1734917400000,1734924600000],[1734930000000,1734937200000]],"highLimit":17.29,"lowLimit":14.15,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"pbRate":19.64,"roa":"--","roe":"--","epsLYR":-0.58,"committee":-0.304478,"marketValue":13231000000,"floatMarketCap":10580000000,"peRate":-35.9405,"changeRate":-0.0471,"turnoverRate":0.0656,"status":1},"requestUrl":"/m/hq/s/300199/tweets","defaultTab":"tweets","newsList":[{"id":"2493927482","title":"翰宇药业（300199）12月20日主力资金净买入7085.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493927482","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493927482?lang=zh_cn&edition=full","pubTime":"2024-12-23 09:10","pubTimestamp":1734916259,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年12月20日收盘，翰宇药业报收于15.72元，上涨12.21%，换手率14.05%，成交量99.24万手，成交额15.06亿元。近5日资金流向一览见下表：翰宇药业融资融券信息显示，融资方面，当日融资买入1.4亿元，融资偿还1.47亿元，融资净偿还680.29万元。翰宇药业主营业务：特色原料药、注射剂、客户定制肽、固体制剂、药品组合包装类产品和医疗器械产品六大系列。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024122300001988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0070","BK0239","300199","BK0188"],"gpt_icon":0},{"id":"2492466072","title":"A股医药板块逆势拉升，鲁抗医药午后涨停，翰宇药业、热景生物涨超10%，成都先导、广誉远、昆药集团、联环药业等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2492466072","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492466072?lang=zh_cn&edition=full","pubTime":"2024-12-20 14:06","pubTimestamp":1734674789,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["600513","BK0070","600771","600789","BK1161","BK0028","BK0077","BK0188","600422","399300","300199","BK0168","BK1515","09939","688068","BK0060","159982","BK0046","688222","BK0216","BK0239","159938","BK1574"],"gpt_icon":0},{"id":"2490007896","title":"翰宇药业旗下公司与龙麻科技签订战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2490007896","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490007896?lang=zh_cn&edition=full","pubTime":"2024-12-11 13:00","pubTimestamp":1733893254,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159891","BK0188","BK0028","BK0239","BK0070","159837","BK0077","300199"],"gpt_icon":0},{"id":"2490061737","title":"12月10日翰宇药业现1笔大宗交易 机构净买入202.95万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490061737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490061737?lang=zh_cn&edition=full","pubTime":"2024-12-10 16:47","pubTimestamp":1733820441,"startTime":"0","endTime":"0","summary":"证券之星消息，12月10日翰宇药业发生大宗交易，交易数据如下：大宗交易成交价格13.53元，成交15万股，成交金额202.95万元，买方营业部为机构专用，卖方营业部为中信证券股份有限公司上海分公司。近三个月该股共发生1笔大宗交易，合计成交1500.0手。该股近期无解禁股上市。截至2024年12月10日收盘，翰宇药业(300199)报收于13.53元，上涨3.44%，换手率10.86%，成交量76.71万手，成交额10.42亿元。该股最近90天内共有1家机构给出评级，买入评级1家。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024121000031478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0070","BK0239","BK0077","BK0188","300199"],"gpt_icon":0},{"id":"2489568454","title":"翰宇药业(300199.SZ)：DS3拟向公司采购约1400万美元GLP-1原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2489568454","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489568454?lang=zh_cn&edition=full","pubTime":"2024-12-05 22:01","pubTimestamp":1733407262,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，近日，公司与DS3 RX LLC(简称“DS3”)签订《产品供应协议》，其拟向公司采购金额价值约1400万美元(折合人民币约1.02亿元)GLP-1原料药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1221108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4590","GLP","BK0077","BK0028","BK4144","BK0239","BK0070","300199","BK0188"],"gpt_icon":0},{"id":"2489431068","title":"翰宇药业最新公告：与DS3签订1.02亿元GLP-1原料药供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2489431068","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489431068?lang=zh_cn&edition=full","pubTime":"2024-12-05 19:01","pubTimestamp":1733396471,"startTime":"0","endTime":"0","summary":"翰宇药业公告，公司与DS3签订《产品供应协议》，DS3拟向公司采购价值约1400万美元（折合人民币约1.02亿元）的GLP-1原料药。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120500031931.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","300199","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2488616582","title":"翰宇药业最新公告：再次收到Hikma的利拉鲁肽注射液采购需求订单","url":"https://stock-news.laohu8.com/highlight/detail?id=2488616582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488616582?lang=zh_cn&edition=full","pubTime":"2024-12-04 18:31","pubTimestamp":1733308291,"startTime":"0","endTime":"0","summary":"翰宇药业公告，公司再次收到美国合作方Hikma的采购需求订单，Hikma拟向公司采购金额为1056.24万美元（约合人民币0.77亿元，含税）的利拉鲁肽注射液（仿制药）。截至本公告披露日，公司与Hikma累计签署合同金额约为3.38亿元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024120400033149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0239","BK0028","BK0070","300199"],"gpt_icon":0},{"id":"2484683573","title":"翰宇药业前总裁被判3年半，与“胡润富豪”共事16年！","url":"https://stock-news.laohu8.com/highlight/detail?id=2484683573","media":"市场资讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484683573?lang=zh_cn&edition=full","pubTime":"2024-11-17 17:02","pubTimestamp":1731834120,"startTime":"0","endTime":"0","summary":" 自称“中国合成多肽第一股”的翰宇药业举报前总裁挪用资金一案获终审判决，公司原董事、高级管理人员袁建成犯挪用资金罪，判处有期徒刑三年六个月。 翰宇药业表示，案件为公司内部自查发现并向公安机关报案，袁建成已于2019年8月从公司离职，自涉嫌犯罪被公安机关采取刑事强制措施之后，公司已经根据相关会计准则计提了相关费用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2024-11-17/doc-incwkiim4503870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0188","300199","BK0070","BK0077","BK0028"],"gpt_icon":0},{"id":"2484509265","title":"概念掘金 | 司美格鲁肽减肥药正式在中国上市，多家电商平台已上线","url":"https://stock-news.laohu8.com/highlight/detail?id=2484509265","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484509265?lang=zh_cn&edition=full","pubTime":"2024-11-17 14:35","pubTimestamp":1731825344,"startTime":"0","endTime":"0","summary":"市场前景广阔","market":"sg","thumbnail":"https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/06664-7e9dde8e-9f54-49fb-a50c-81a04f916999.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/1336126","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0070","LU1093756325.SGD","LU2148510915.USD","BK0028","LU0154236417.USD","688076","BK4532","LU0405327148.USD","BK0077","688117","BK0188","600276","LU1064130708.USD","300199","BK0132","01801","NVO","BK4588","LU0405327494.USD","BK0042","BK0196","BK0114","BK0060","603456","BK0251","IE00BKVL7J92.USD","002821","IE00BZ1G4Q59.USD","BK0201","LU1064131003.USD","BK0113","300003","BK0183","LU2488822045.USD","BK4585","BK0239","LU1093756168.USD","LU1328615791.USD","BK4007","BK0012"],"gpt_icon":1},{"id":"2483071625","title":"翰宇药业：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2483071625","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483071625?lang=zh_cn&edition=full","pubTime":"2024-11-13 18:20","pubTimestamp":1731493244,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300199","BK0239","BK0077","BK0028","BK0188","BK0070"],"gpt_icon":0},{"id":"2483071458","title":"翰宇药业最新公告：原董事袁建成挪用资金罪终审裁定 被判处有期徒刑三年六个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2483071458","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483071458?lang=zh_cn&edition=full","pubTime":"2024-11-13 18:20","pubTimestamp":1731493210,"startTime":"0","endTime":"0","summary":"翰宇药业公告，公司原董事、高级管理人员袁建成犯挪用资金罪一案，已收到广东省深圳市中级人民法院的终审裁定。袁建成因利用职务便利，挪用公司资金1685万元归个人使用，被判处有期徒刑三年六个月。该案已审结。袁建成所涉犯罪行为发生在六年前，且其已于2019年8月从公司离职。公司已根据相关会计准则计提了相关费用。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111300030394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0077","BK0188","BK0070","BK0028","BK0239"],"gpt_icon":0},{"id":"2479760039","title":"翰宇药业（300199）2024年三季报简析：亏损收窄，短期债务压力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2479760039","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479760039?lang=zh_cn&edition=full","pubTime":"2024-10-31 06:39","pubTimestamp":1730327993,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期翰宇药业发布2024年三季报。截至本报告期末，公司营业总收入3.75亿元，同比下降6.56%，归母净利润-3480.56万元，同比上升80.72%。本报告期翰宇药业短期债务压力上升，流动比率达0.62。本次财报公布的各项数据指标表现一般。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100009286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","300199","BK0188","BK0070","BK0239"],"gpt_icon":0},{"id":"2479032664","title":"翰宇药业最新公告：第三季度净利润亏损2444.68万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479032664","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479032664?lang=zh_cn&edition=full","pubTime":"2024-10-29 19:41","pubTimestamp":1730202060,"startTime":"0","endTime":"0","summary":"翰宇药业发布2024年第三季度报告，前三季度实现营业收入3.75亿元，同比下降6.56%；归属于上市公司股东的净利润亏损3480.56万元。第三季度实现营业收入1.19亿元，同比增长56.67%；归属于上市公司股东的净利润亏损2444.68万元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900036873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"gpt_icon":0},{"id":"2479472927","title":"翰宇药业最新公告：“醋酸阿托西班注射液”获得泰国上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2479472927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479472927?lang=zh_cn&edition=full","pubTime":"2024-10-29 18:50","pubTimestamp":1730199012,"startTime":"0","endTime":"0","summary":"翰宇药业公告，公司产品“醋酸阿托西班注射液”获得泰国食品药品监督管理局下发的《药品注册证书》，获得了泰国的上市许可。该药品适用于有早产指征的妊娠妇女，用于推迟即将出现的早产。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900035002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0239","BK0077","BK0028","BK0188","BK0070"],"gpt_icon":0},{"id":"2476111022","title":"翰宇药业最新公告：Hikma拟向公司采购约8400万元利拉鲁肽注射液","url":"https://stock-news.laohu8.com/highlight/detail?id=2476111022","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476111022?lang=zh_cn&edition=full","pubTime":"2024-10-17 18:31","pubTimestamp":1729161062,"startTime":"0","endTime":"0","summary":"翰宇药业公告，公司收到美国合作方Hikma的采购需求订单，其拟向公司采购金额为1173.60万美元（约合人民币0.84亿元（含税））的利拉鲁肽注射液（仿制药）。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101700027969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0070","BK0239","BK0077","BK0188","300199"],"gpt_icon":0},{"id":"2476350211","title":"A股减肥药板块局部异动，常山药业直线拉升逼近20CM涨停，博瑞医药、翰宇药业、金凯生科、百花医药等跟涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2476350211","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476350211?lang=zh_cn&edition=full","pubTime":"2024-10-17 10:22","pubTimestamp":1729131779,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["300255","BK0028","BK0077","159982","BK0172","300199","600721","BK0188","688166","301509","BK0070","BK0239","399300","BK0216","BK0102"],"gpt_icon":0},{"id":"2475334076","title":"翰宇药业(300199.SZ)：利拉鲁肽注射液上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2475334076","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475334076?lang=zh_cn&edition=full","pubTime":"2024-10-14 16:21","pubTimestamp":1728894060,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)公告，公司于2024年10月12日收到国家药品监督管理局签发的利拉鲁肽注射液《受理通知书》。该品用于成人2型糖尿病患者控制血糖，适用于单用二甲双胍或磺脲类药物最大可耐受剂量治疗后血糖仍控制不佳的患者，与二甲双胍或磺脲类药物联合应用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1193357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0070","300199","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2470256742","title":"翰宇药业最新公告：司美格鲁肽原料药获得DMF备案号","url":"https://stock-news.laohu8.com/highlight/detail?id=2470256742","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470256742?lang=zh_cn&edition=full","pubTime":"2024-09-25 20:10","pubTimestamp":1727266253,"startTime":"0","endTime":"0","summary":"翰宇药业公告，公司收到美国食品药品监督管理局（FDA）的确认，公司司美格鲁肽原料药获得DMF（Drug Master File）备案号。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092500031984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0070","BK0028","BK0188","300199"],"gpt_icon":0},{"id":"2470256897","title":"翰宇药业：司美格鲁肽原料药获得DMF备案号","url":"https://stock-news.laohu8.com/highlight/detail?id=2470256897","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470256897?lang=zh_cn&edition=full","pubTime":"2024-09-25 20:04","pubTimestamp":1727265848,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["DMF","BK0077","BK0070","300199","BK0188","BK0239","BK0028"],"gpt_icon":0},{"id":"2470523761","title":"翰宇药业(300199.SZ)：司美格鲁肽原料药获美国DMF备案号","url":"https://stock-news.laohu8.com/highlight/detail?id=2470523761","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470523761?lang=zh_cn&edition=full","pubTime":"2024-09-25 18:50","pubTimestamp":1727261422,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)公告，公司收到美国食品药品监督管理局(FDA)的确认，公司司美格鲁肽原料药获得DMF备案号。司美格鲁肽是一种GLP-1受体激动剂，通过增加胰岛素释放、降低胰高血糖素释放量、延缓胃排空和降低食欲发挥作用。司美格鲁肽用于减轻特定患者的体重，并降低2型糖尿病患者的血糖水平和降低主要心血管事件(如心脏病发作或中风)的风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1187115.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["DMF","BK0239","BK0188","300199","BK0070","BK0077","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","stockEarnings":[{"period":"1week","weight":0.2262},{"period":"1month","weight":0.2576},{"period":"3month","weight":0.7275},{"period":"6month","weight":0.3424},{"period":"1year","weight":0.1828},{"period":"ytd","weight":0.1576}],"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","perCapita":"11874股","boardName":"医药制造业","registeredCapital":"88324万元","compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0},{"period":"3month","weight":0.2307},{"period":"6month","weight":0.1234},{"period":"1year","weight":0.154},{"period":"ytd","weight":0.1321}],"survey":" 深圳翰宇药业股份有限公司是一家专业从事多肽药物研发、生产和销售的国家级高新技术企业，主要产品包括多肽制剂药品、多肽原料药、客户定制肽、美容肽、固体制剂药品、医疗器械、多肽护肤品、大健康类产品等多个系列。公司上榜2023年广东制造业企业500强，并获得深圳市“专精特新”企业认定；翰宇武汉公司荣膺黄陂区“优秀先进制造业企业”，再次凸显公司高水准的质量优势。","serverTime":1734923082237,"listedPrice":30.19,"stockholders":"59478人(较上一季度减少4.98%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}